Today: 10 June 2026
Browse Category

NYSE:UR 30 January 2026

Stock Market Today

  • LVMH Stock Slides After Rally; RBC Maintains Buy with €600 Target
    June 10, 2026, 5:21 AM EDT. LVMH shares dipped to €489.90 on Wednesday, retreating after a four-day rally amid a 24% decline since January. RBC reaffirmed its Buy rating and maintained a €600 price target, citing potential recovery tied to July's first-half results. Investors are focused on Fashion & Leather Goods, LVMH's largest segment, which saw a 2% organic revenue drop in Q1. Other divisions like Watches & Jewelry and Wines & Spirits showed positive growth gains. The company's market capitalization stands at approximately €244 billion. Despite recent volatility, RBC's outlook hinges on easing regional pressures, especially in the Middle East, and signs of revived brand momentum critical for stock value.

Latest articles

SoFi Stock Faces a Crucial Pre-Market Test as Wall Street Turns Defensive

10 June 2026
Rolls-Royce shares rebounded 1.5% in London after Tuesday’s 2.68% drop, as investors weighed fresh airline criticism over engine delays against the company’s reaffirmed 2026 profit and cash flow guidance; CEO Tufan Erginbilgic said Rolls had a “strong start to the year,” but risks remain if airline pressure leads to higher costs or slower cash conversion.
LVMH Drops Following Quick Rally, RBC Still Sees Recovery for Luxury

LVMH Drops Following Quick Rally, RBC Still Sees Recovery for Luxury

10 June 2026
LVMH shares slipped 0.49% to €489.90 in Paris after a four-day rebound, as investors weighed RBC’s reiterated Buy rating with a €600 target against ongoing 2026 losses and a 24% year-to-date drop; all eyes now turn to July’s first-half results for signs of recovery in Fashion & Leather Goods and any relief from Middle East weakness.
Roche Shares Edge Up After $2.3 Billion Nurix Cancer Pact

Roche Shares Edge Up After $2.3 Billion Nurix Cancer Pact

10 June 2026
Roche’s participation certificates climbed 1.07% to CHF 322.20 after announcing a $2.3 billion deal with Nurix Therapeutics for late-stage blood-cancer drug bexobrutideg, planned to enter Phase 3 trials this summer in CLL, as investors weigh the asset’s potential to offset losses from expiring patents and drive mid-single-digit sales growth in 2026.
YY Group Shares Jump Premarket on Humanoid Robot Move

YY Group Shares Jump Premarket on Humanoid Robot Move

10 June 2026
YYGH jumped to $0.19 in early pre-market after announcing deployment of Unitree G1 humanoid robots for facility management, aiming to turn operational know-how into higher-margin data assets, but the stock remains volatile near record lows after a recent reverse split and has not confirmed robot-driven revenue or margin gains.
Tencent Shares Gain After $4.66B Bond Sale Seen Fueling AI Bets

Tencent Shares Gain After $4.66B Bond Sale Seen Fueling AI Bets

10 June 2026
Tencent shares jumped 3.22% to HK$467.80 after the company priced a larger-than-expected US$4.66 billion dual-currency bond deal, drawing over US$17 billion in orders and allowing tighter pricing, as investors weighed Tencent’s ability to fund rising AI investments while maintaining strong cash flow and ongoing share buybacks.
Go toTop